Spasticity Management in Multiple Sclerosis Evidence-Based Management Strategies for Spasticity Treatment in Multiple Sclerosis

[1]  L. Vodovnik,et al.  Effects of electrical stimulation on spinal spasticity. , 2020, Scandinavian journal of rehabilitation medicine.

[2]  A. Thompson,et al.  Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  M. Namey,et al.  Adherence to disease-modifying therapy in multiple sclerosis: Part II. , 2001, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.

[4]  A. Bowling.  Alternative Medicine and Multiple Sclerosis , 2001 .

[5]  N. Hyman,et al.  Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[6]  T. K. Larsen,et al.  Effect of baclofen on gait in spastic MS patients. , 2000, Acta neurologica Scandinavica.

[7]  T. Sinkjær,et al.  Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients , 2000, Multiple sclerosis.

[8]  W. Peacock,et al.  The surgical treatment of spasticity , 2000, Muscle & nerve.

[9]  T. Sinkjær,et al.  Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis , 2000, Muscle & nerve.

[10]  S C Gupta,et al.  Gait characteristics of individuals with multiple sclerosis before and after a 6-month aerobic training program. , 1999, Journal of rehabilitation research and development.

[11]  L Mendozzi,et al.  Physical rehabilitation has a positive effect on disability in multiple sclerosis patients , 1999, Neurology.

[12]  A. Thompson,et al.  *The Impact of In-patient Rehabilitation on Disability and Handicap in Progressive Multiple Sclerosis: A randomised controlled trial , 1998 .

[13]  S. Nadeau,et al.  Cold effect on oxygen uptake, perceived exertion, and spasticity in patients with multiple sclerosis. , 1998, Archives of physical medicine and rehabilitation.

[14]  M. Staal,et al.  Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity , 1997, Journal of neurology, neurosurgery, and psychiatry.

[15]  A J Thompson,et al.  The impact of inpatient rehabilitation on progressive multiple sclerosis , 1997, Annals of neurology.

[16]  T. Vollmer,et al.  Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. , 1997, Archives of neurology.

[17]  W. Olson,et al.  Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. , 1997, Archives of physical medicine and rehabilitation.

[18]  U. Maisch,et al.  The effects of therapy on spasticity utilizing a motorized exercise-cycle , 1997, Spinal Cord.

[19]  T. Sinkjaer,et al.  Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study , 1996, Multiple sclerosis.

[20]  J. Tonn,et al.  Functional Outcome and Clinical Significance of Long-term Intrathecal Baclofen Therapy for Severe Spasticity , 1996 .

[21]  B. Conrad,et al.  Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[22]  W. Becker,et al.  Long Term Intrathecal Baclofen Therapy in Patients with Intractable Spasticity , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  T. Sinkjaer,et al.  A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[24]  F. Lublin,et al.  Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial , 1994, Neurology.

[25]  R. Roberts,et al.  Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). , 1994, Journal of neurology, neurosurgery, and psychiatry.

[26]  R. Penn,et al.  Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. , 1993, Journal of neurosurgery.

[27]  PG Mattison.  Transcutaneous electrical nerve stimulation in the management of painful muscle spasm in patients with multiple sclerosis , 1993 .

[28]  Elizabeth Livesley.  Effects of electrical neuromuscular stimulation on functional performance in patients with multiple sclerosis , 1992 .

[29]  R. Penn.  Intrathecal baclofen for spasticity of spinal origin: seven years of experience. , 1992, Journal of neurosurgery.

[30]  M. B. Smith,et al.  Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. , 1991, Archives of physical medicine and rehabilitation.

[31]  D B Calne,et al.  Treatment of spasticity with botulinum toxin: A double‐blind study , 1990, Annals of neurology.

[32]  Y. Lazorthes,et al.  Chronic intrathecal baclofen administration for control of severe spasticity. , 1990, Journal of neurosurgery.

[33]  G. Rice,et al.  Effect of Bile Duct Ligation-Induced Liver Damage on the Blood-brain Barrier , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  M. Latash,et al.  Intrathecal Baclofen for Severe Spinal Spasticity , 1989, The New England journal of medicine.

[35]  P. Lagassé,et al.  Functional electrical stimulation and the reduction of co-contraction in spastic biceps brachii , 1989 .

[36]  J. Opara,et al.  Treatment of spinal spasticity by electrical stimulation. , 1988, Journal of biomedical engineering.

[37]  J. Minderhoud,et al.  Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients , 1988, Acta neurologica Scandinavica.

[38]  G. Ellison,et al.  Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. , 1988, Advances in alcohol & substance abuse.

[39]  B. Weinshenker,et al.  Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis , 1988, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[40]  Y. Lapierre,et al.  Treatment of Spasticity with Tizanidine in Multiple Sclerosis , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[41]  H. Nordal,et al.  The treatment of spasticity in multiple sclerosis: a double‐blind clinical trial of a new anti‐spastic drug tizanidine * compared with baclofen , 1987, Acta neurologica Scandinavica.

[42]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[43]  S. Braver,et al.  The measurement of clinical pain intensity: a comparison of six methods , 1986, Pain.

[44]  J. Basmajian,et al.  Ketazolam treatment for spasticity: double-blind study of a new drug. , 1984, Archives of physical medicine and rehabilitation.

[45]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[46]  C. Ellenberger,et al.  Treatment of Human Spasticity with Δ9‐Tetrahydrocannabinol , 1981 .

[47]  D. Paty,et al.  The Use of Baclofen in Treatment of Spasticity in Multiple Sclerosis , 1979, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[48]  M. Kelly-Hayes,et al.  Baclofen for spasticity in multiple sclerosis Double‐blind crossover and three‐year study , 1978, Neurology.

[49]  B. Sachais,et al.  Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. , 1977, Archives of neurology.

[50]  D. M. Dooley,et al.  Electrical stimulation of the spinal cord in patients with demyelinating and degenerative diseases of the central nervous system. , 1981, Applied neurophysiology.

[51]  R. Wührich.  [Treatment of multiple sclerosis]. , 1976, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

[52]  R. Spehlmann,et al.  Comparison of dantrolene sodium and diazepam in the treatment of spasticity. , 1976, Journal of neurology, neurosurgery, and psychiatry.

[53]  D. Hedley,et al.  Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis , 1975, Postgraduate medical journal.

[54]  Basmajian Jv.  Lioresal (baclofen) treatment of spasticity in multiple sclerosis. , 1975 .

[55]  A. Heltberg,et al.  A DOUBLE‐BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS , 1975, Acta neurologica Scandinavica.

[56]  Y. Lapierre,et al.  The antispastic effects of Ba 34647 (B-4-p-chlorophenyl-gamma-amino-butyric acid) a GABA derivative. , 1974, Current therapeutic research, clinical and experimental.

[57]  J. Basmajian,et al.  Effects of a GABA--derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study. , 1974, American Journal of Physical Medicine.

[58]  P. Hudgson,et al.  A comparison of baclofen and diazepam in the treatment of spasticity. , 1974, Journal of the neurological sciences.

[59]  A. Gelenberg,et al.  The effect of dantrolene sodium on spasticity in multiple sclerosis , 1973, Neurology.

[60]  M. Polikar,et al.  Results of international clinical trials with Lioresal. , 1972, Postgraduate medical journal.

[61]  B. A. Wolf.  Effects of temperature reduction on multiple sclerosis. , 1970, Physical therapy.

[62]  B. Ashworth.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. , 1964, The Practitioner.

[63]  O. Miglietta.  EVALUATION OF COLD IN SPASTICITY , 1962, American journal of physical medicine.

[64]  Watson Cw.  Effect of Lowering of Body Temperature on the Symptoms and Signs of Multiple Sclerosis , 1959 .

[65]  P. Garramone,et al.  Observations on the effects of cool baths for patients with multiple sclerosis. , 1959, The Physical therapy review.

[66]  J. Halper.  Advanced concepts in multiple sclerosis nursing care , 2001 .

[67]  B. Brouwer,et al.  The effects of slow stroking on spasticity in patients with multiple sclerosis: A pilot study , 1995 .

[68]  A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. , 1994, Neurology.

[69]  J. González-Darder,et al.  Use of intrathecal baclofen administered by programmable infusion pumps in resistent spasticity. , 1989, Acta neurochirurgica. Supplementum.

[70]  M. Sánchez-Ledesma,et al.  Critical approach to intrastriatal medullary adrenal implants via open surgery in parkinsonism. Case report. , 1989, Acta neurochirurgica. Supplementum.

[71]  G. Serratrice,et al.  Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. , 1988, Current medical research and opinion.

[72]  G. Rea,et al.  Intrathecal application of drugs for muscle hypertonia. , 1988, Scandinavian journal of rehabilitation medicine. Supplement.

[73]  P. Rossini,et al.  Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: A double-blind, cross-over study in comparison with placebo , 1983 .

[74]  V. Alfieri.  Electrical treatment of spasticity. Reflex tonic activity in hemiplegic patients and selected specific electrostimulation. , 1982, Scandinavian journal of rehabilitation medicine.

[75]  S. Muff,et al.  A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. , 1981, Current medical research and opinion.

[76]  C. Ellenberger,et al.  Treatment of human spasticity with delta 9-tetrahydrocannabinol. , 1981, Journal of clinical pharmacology.

[77]  G Broggi,et al.  Electrical spinal cord stimulation for spastic movement disorders. , 1981, Applied neurophysiology.

[78]  J. Siegfried.  Treatment of spasticity by dorsal cord stimulation. , 1980, International rehabilitation medicine.

[79]  M. Dimitrijevic,et al.  Neurophysiological evaluation of chronic spinal cord stimulation in patients with upper motor neuron disorders. , 1980, International rehabilitation medicine.

[80]  F. Gračanin.  Functional electrical stimulation in control of motor output and movements. , 1978, Electroencephalography and clinical neurophysiology. Supplement.

[81]  Bates Ja.  Therapeutic electrical stimulation. The transistorized placebo , 1978 .

[82]  W. Cendrowski,et al.  Clonazepam, baclofen and placebo in the treatment of spasticity. , 1977, European neurology.

[83]  R. Spehlmann,et al.  Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam. , 1975, Transactions of the American Neurological Association.

[84]  L. Sheplan,et al.  Spasmolytic properties of dantrolene sodium: clinical evaluation. , 1975, Military medicine.

[85]  W. H. Jeffreys,et al.  Effects of induced hyperthermia on some neurological diseases. , 1958, A.M.A. archives of neurology and psychiatry.